Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Good News For A Change At Genzyme: Consent Decree Finalized Without Surprises, Lumizyme Approved By FDA Ahead Of Schedule

Executive Summary

Belying the adage that no news is good news, embattled Genzyme enjoyed two measures of positive news in the past week. But activist investors continue circling the company, which is not yet out of the deep water
Advertisement

Related Content

In Manufacturing, Absence Of Evidence Is Not Evidence Of Absence, FDA Tells BioMarin
Bydureon Approval Provides Lesson In Clinical Data Requirements For Biosimilars
CSL Behring's Corifact Clears FDA On 14-Patient Trial
CSL Behring's Corifact Clears FDA On 14-Patient Trial
BioMarin Refreshes Its Pipeline With ZyStor Acquisition
Finalized Consent Decree For Allston Largely In Line With Genzyme's Expectations
Genzyme, Industry Analysts Relieved By Particulars In Draft Consent Decree
Genzyme's Manufacturing Problems Lead To Enforcement Action By FDA
Genzyme Receives Complete Response, Warning Letters For Lumizyme
Genzyme Receives Complete Response, Warning Letters For Lumizyme

Topics

Advertisement
UsernamePublicRestriction

Register

PS052280

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel